IDD Therapeutics
Drug Discovery Platform for Cancer Treatments
Company Overview
Snapshot
Founded in January 2010 by Anwar Rayan, IDD Therapeutics operates with 1-10 employees. The company has secured funding across one round from Office of the Chief Scientist. IDD Therapeutics is developing targeted small-molecule New Therapeutic Entities (NTEs) for cancer therapy, including drug candidates IDD-1010, IDD-1040, and IDD-2010.
Business overview
IDD Therapeutics Ltd specializes in developing drugs for cancer therapy, focusing on improving the safety and efficacy of existing treatments. The company leverages its proprietary Intelligent Learning Engine (ILE) to design targeted small-molecule New Therapeutic Entities (NTEs). Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, IDD Therapeutics serves the Life Sciences and Pharmaceutical industries with products like IDD-1010, IDD-1040, and IDD-2010.
Company Intelligence Q&A
- Who founded IDD Therapeutics?
- IDD Therapeutics was founded by Anwar Rayan.
- What is IDD Therapeutics' primary focus?
- IDD Therapeutics primarily focuses on developing drugs for cancer therapy, aiming to improve the safety and efficacy of existing treatments and protocols.
- What technology does IDD Therapeutics use for drug discovery?
- IDD Therapeutics utilizes its proprietary Intelligent Learning Engine (ILE) to help researchers design targeted small-molecule New Therapeutic Entities (NTEs) for cancer therapy.
- What are some of IDD Therapeutics' drug candidates?
- IDD Therapeutics is developing drug candidates such as IDD-1010, IDD-1040, and IDD-2010, with IDD-1040 being a targeted, multifunctional Mode of Action (MoA) NTE.
- What is the current product stage of IDD Therapeutics' offerings?
- IDD Therapeutics' products are currently in the R&D stage, with IDD-1010 and IDD-2010 at the early preclinical stage, and IDD-1040 being a small molecule synthesized in a one-step chemical procedure.